AWAT1 Antibody

What is AWAT1 and what is its biological significance in research?

AWAT1 (Acyl-CoA wax alcohol acyltransferase 1) belongs to the diacylglycerol acyltransferase family and plays a central role in lipid metabolism in skin. This enzyme esterifies long chain (wax) alcohols with acyl-CoA-derived fatty acids to produce wax esters that are enriched in sebum. Its predominant expression in sebaceous glands suggests a specialized function in skin lipid production . As a member of the DGAT2L3 family (also known as DGA2), AWAT1 is encoded by a gene located on chromosome Xq13.1 with 7 exons . Research on AWAT1 is particularly relevant for understanding sebaceous gland function and lipid metabolism disorders affecting the skin.

How should researchers select the appropriate AWAT1 antibody for their specific applications?

Selection should be based on:

• Target application compatibility: Different antibodies are validated for specific applications:

  • Western blot (WB) and ELISA applications are supported by multiple antibodies

  • Immunocytochemistry (ICC) and immunofluorescence (IF) require antibodies specifically validated for these techniques

• Species reactivity requirements: Available antibodies offer varying cross-reactivity profiles:

• Epitope considerations: Antibodies targeting different regions may yield different results:

  • C-terminal region antibodies (e.g., ABIN7184811)

  • N-terminal region antibodies

  • Full-length protein antibodies (e.g., ABIN2589535)

What experimental validation data should researchers expect when selecting an AWAT1 antibody?

Researchers should look for:

• Western blot validation: Verification of target band at expected molecular weight (37 kDa for AWAT1)

• Multiple application validation: Antibodies tested in several techniques provide greater confidence

• Validation in relevant cell lines/tissues: Ideally, antibodies should be tested in sebaceous gland samples or relevant cell models

• Cross-reactivity testing: Documentation of specificity against related proteins in the DGAT family

• Number of validation experiments: Some vendors report multiple validation experiments (e.g., "(3)" validation data points for certain antibodies)

What are the optimal conditions for Western blotting with AWAT1 antibodies?

For successful Western blotting:

• Sample preparation: Use complete lysis buffers containing detergents and protease inhibitors to extract membrane-associated AWAT1

• Dilution optimization:

  • Primary antibody: Begin with manufacturer-recommended dilutions (typically 1:500-1:2000)

  • Secondary antibody: Use compatible anti-rabbit or anti-mouse IgG depending on host species

• Expected molecular weight: Verify bands at approximately 37 kDa

• Recommended controls:

  • Positive controls: Sebaceous gland-derived samples

  • Negative controls: AWAT1-deficient tissues or knockdown samples

  • Loading controls: GAPDH, β-actin or similar housekeeping proteins

• Compatible secondary antibodies: Suitable options include:

  • Goat Anti-Rabbit IgG H&L Antibody (AP) (A294874)

  • Goat Anti-Rabbit IgG H&L Antibody (HRP) (A294888)

How should researchers optimize immunohistochemistry protocols for AWAT1 detection?

Optimal IHC conditions include:

• Tissue fixation: Standard formalin fixation is suitable, but avoid overfixation

• Antibody dilution range: Begin with 1:20-1:50 for IHC applications

• Antigen retrieval methods: Heat-induced epitope retrieval may be necessary (test both citrate pH 6.0 and EDTA pH 9.0 buffers)

• Detection systems: HRP-based or fluorescence-based detection systems are both applicable

• Critical controls:

  • Isotype controls (e.g., Rabbit IgG A82272 or A17360 for rabbit polyclonal antibodies)

  • Tissue controls: Include sebaceous gland-rich skin sections as positive controls

What methodological approaches can researchers use to validate AWAT1 antibody specificity?

Comprehensive validation approaches include:

• Peptide competition assays: Pre-incubate antibody with the immunizing peptide (e.g., synthetic peptide derived from human AWAT1 C-terminal region for ABIN7184811)

• Genetic knockout/knockdown controls: Test antibody reactivity in AWAT1-deficient samples

• Multi-antibody verification: Compare results using antibodies targeting different AWAT1 epitopes

• Cross-reactivity assessment: Evaluate potential cross-reactivity with related DGAT family proteins

• Affinity purification verification: Most commercial AWAT1 antibodies are affinity-purified using the immunizing peptide

How can researchers effectively use AWAT1 antibodies in co-localization studies?

For successful co-localization experiments:

• Compatible fluorophore selection: When using fluorescently labeled secondary antibodies, ensure spectral separation between channels

• Recommended antibody combinations:

  • AWAT1 (rabbit polyclonal) paired with organelle markers (mouse monoclonal)

  • Use cross-adsorbed secondary antibodies to prevent species cross-reactivity

• Fixation considerations: Use 4% paraformaldehyde or methanol fixation based on epitope accessibility

• Antibody concentration: For immunofluorescence, start with more concentrated dilutions than used for WB (approximately 1:50-1:200)

• Controls for co-localization:

  • Single-stained controls to assess bleed-through

  • Non-permeabilized controls to assess membrane localization

What approaches can resolve contradictory results from different AWAT1 antibodies?

When facing contradictory results:

• Epitope mapping analysis: Compare the epitope regions of different antibodies:

  • C-terminal targeting antibodies (amino acids 261-310)

  • Internal region antibodies (amino acids 107-156)

  • Full-length protein antibodies (amino acids 1-328)

• Validation hierarchy implementation:

  • Prioritize results from antibodies with more extensive validation data

  • Consider antibodies purified by affinity chromatography using the immunizing peptide

  • Validate findings with functional assays (e.g., enzyme activity measurements)

• Technical troubleshooting:

  • Test different sample preparation methods to ensure epitope accessibility

  • Evaluate potential post-translational modifications affecting epitope recognition

  • Assess the possibility of isoform-specific recognition

How can researchers quantify AWAT1 expression levels in comparative studies?

For accurate quantification:

• Western blot densitometry:

  • Use standard curves with recombinant AWAT1 protein

  • Normalize to loading controls (GAPDH, β-actin)

  • Analyze in the linear range of detection

• ELISA-based quantification:

  • For AWAT1 antibodies validated for ELISA (e.g., A101203, ABIN7184811)

  • Use recommended dilutions (approximately 1:1000 to 1:5000)

  • Include standard curves using recombinant AWAT1 protein

• Immunohistochemistry quantification:

  • Use digital image analysis software

  • Standardize acquisition parameters

  • Calculate H-scores or percent positive cells

How should researchers address weak or non-specific signals in AWAT1 Western blots?

For weak signals:

• Increase antibody concentration: Adjust from 1:2000 toward 1:500

• Optimize protein loading: Increase total protein amount (30-50 μg)

• Enhance detection sensitivity: Use high-sensitivity ECL substrates

• Extend exposure time: Gradually increase exposure while monitoring background

• Sample preparation optimization: Use different lysis buffers to improve AWAT1 extraction

For non-specific signals:

• Increase blocking stringency: Test 5% BSA vs. 5% non-fat milk

• Optimize antibody dilution: If background is high, dilute further

• Extend washing steps: Add additional washes with 0.1% Tween-20

• Pre-absorb antibody: Incubate with non-relevant tissues to remove non-specific antibodies

• Use alternative antibody: Try antibodies targeting different epitopes

What factors affect reproducibility in AWAT1 antibody-based experiments?

Key reproducibility factors include:

• Antibody storage conditions:

  • Store at -20°C in aliquots to avoid freeze-thaw cycles

  • Some antibodies are shipped at 4°C but require -20°C for long-term storage

• Sample preparation consistency:

  • Standardize lysis buffers and extraction protocols

  • Maintain consistent protein concentration determination methods

• Experimental conditions standardization:

  • Use consistent blocking reagents (PBS with 50% glycerol, 0.5% BSA and 0.02% sodium azide)

  • Maintain consistent incubation times and temperatures

• Antibody lot-to-lot variation:

  • Document lot numbers

  • Validate new lots against previous results

What research design considerations are important when studying AWAT1 in disease models?

For disease model studies:

• Appropriate controls selection:

  • Age and sex-matched controls (especially important as AWAT1 is on X chromosome)

  • Same genetic background in animal models

• Sample size determination:

  • Power analysis based on expected effect size

  • Multiple biological replicates (n≥3)

• Technical validation approaches:

  • Confirm antibody specificity in disease tissue

  • Correlate protein data with mRNA expression

  • Use multiple detection methods (WB, IHC, IF)

• Multi-parameter analysis:

  • Correlate AWAT1 expression with functional outcomes

  • Assess related pathway components

  • Consider tissue-specific expression patterns